Overview
Qtern Tablets combine Saxagliptin (5 mg), a DPP-4 inhibitor, and Dapagliflozin (10 mg), an SGLT2 inhibitor, to effectively manage type 2 diabetes mellitus in adults. This dual-action therapy helps improve glycemic control by increasing insulin secretion, reducing glucose reabsorption in the kidneys, and enhancing urinary glucose excretion. Qtern is suitable for patients who need additional control beyond monotherapy or metformin.





